Aiforia Technologies Secures Exclusive AI Partnership in France

Aiforia Technologies Oyj has been appointed the sole AI collaborator for the French PROSTIA project, augmenting its clinical relationship with Assistance Publique-Hôpitaux de Paris (AP-HP) from two to seven hospitals. This partnership marks a significant deployment of Aiforia's AI model in prostate cancer diagnostics, validated by its selection under the France 2030 program supported by Bpifrance.

Although financial specifics remain undisclosed, estimates suggest the analysis of 30,000 whole slide images annually, potentially generating €150,000 to €300,000 in recurring revenue. The project may expand to cover other prevalent cancers, impacting procurement strategies and broadening AI adoption amid a declining pathologist workforce.

No changes are anticipated in Aiforia's FY26 sales forecast of €6 million. These developments reinforce Aiforia's positioning as a market leader and affirm future growth expectations, supporting the continued "BUY" recommendation with a target price of €3.80.